Oppenheimer & CO Inc Syndax Pharmaceuticals Inc Transaction History

Oppenheimer & CO Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 24, 2019	SELL	$4.26 - $6.86 $84,386 - $135,889	-19,809 Closed	0 $0
Q4 2018 Jan 29, 2019	BUY	$3.6 - $8.42 $795 - $1,860	221 Added 1.13%	19,809 $88,000
Q3 2018 Oct 26, 2018	BUY	$6.33 - $8.08 $27,288 - $34,832	4,311 Added 28.22%	19,588 $158,000
Q2 2018 Aug 10, 2018	SELL	$6.93 - $14.63 $9,521 - $20,101	-1,374 Reduced 8.25%	15,277 $107,000
Q1 2018 May 01, 2018	BUY	$8.71 - $14.82 $19,083 - $32,470	2,191 Added 15.15%	16,651 $237,000
Q4 2017 Feb 07, 2018	SELL	$7.8 - $12.94 $104,013 - $172,554	-13,335 Reduced 47.98%	14,460 $127,000
Q3 2017 Nov 09, 2017	BUY	$10.9 - $12.73 $302,965 - $353,830	27,795	27,795 $325,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $882M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.